Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) Stock Has Consensus Price Target of $8.33

Shares of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX – Get Free Report) have received a consensus rating of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $5.75.

A number of research analysts recently issued reports on IMDX shares. Wall Street Zen upgraded shares of Insight Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insight Molecular Diagnostics in a report on Monday, September 21st. Stephens reiterated an “equal weight” rating and set a $4.00 target price on shares of Insight Molecular Diagnostics in a research report on Wednesday. BTIG Research reissued a “neutral” rating and issued a $1.00 price target on shares of Insight Molecular Diagnostics in a research report on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of Insight Molecular Diagnostics in a research note on Tuesday, August 18th.

Get Our Latest Research Report on Insight Molecular Diagnostics

Insider Buying and Selling

In related news, major shareholder Broadwood Partners, L.P. bought 3,428,571 shares of Insight Molecular Diagnostics stock in a transaction on Tuesday, November 17th. The stock was acquired at an average price of $1.75 per share, with a total value of $5,999,999.25. Following the acquisition, the insider directly owned 16,113,455 shares of the company’s stock, valued at $28,198,546.25. This represents a 27.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.21% of the company’s stock.

Insight Molecular Diagnostics Stock Up 17.5%

IMDX opened at $1.95 on Thursday. The stock has a market cap of $63.88 million, a price-to-earnings ratio of -1.56 and a beta of 1.90. The business has a 50 day moving average of $3.05 and a 200-day moving average of $4.43. Insight Molecular Diagnostics has a 12-month low of $1.50 and a 12-month high of $7.51.

Insight Molecular Diagnostics (NASDAQ:IMDX – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.19) EPS for the quarter. The business had revenue of $0.56 million during the quarter.

About Insight Molecular Diagnostics

(Get Free Report)

Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.

Recommended Stories

Analyst Recommendations for Insight Molecular Diagnostics (NASDAQ:IMDX)

Receive News & Ratings for Insight Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insight Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.